The $3 Trillion Cardiometabolic Crisis: Mapping the Global Burden of Obesity, Diabetes, and MASH

Cardiometabolic disease has become one of the defining public health challenges of the 21st century. The World Health Organization (WHO) estimates that more than one billion people globally lived with obesity by 2025, a figure that has nearly tripled since 1975. The economic burden associated with overweight and obesity is projected to reach approximately $3 trillion annually by 2030, according to the World Obesity Federation.

This expanding disease burden is driving unprecedented demand for new metabolic therapies. Drugs originally developed to treat diabetes—particularly GLP-1 receptor agonists and multi-receptor incretin therapies—are increasingly being positioned as core interventions for a broader cluster of cardiometabolic conditions that includes type 2 diabetes, cardiovascular disease, and metabolic liver disease.

Analysts increasingly view the cardiometabolic market as a multi-decade opportunity for pharmaceutical innovation. According to projections published in The Lancet, more than 60% of the global adult population (approximately 3.8 billion people) are forecast to be living with overweight or obesity by 2050, creating sustained demand for therapies that address the systemic consequences of metabolic dysfunction.

Diabetes: The Core Driver of Cardiometabolic Disease

Type 2 diabetes remains the central pillar of the global cardiometabolic crisis. The International Diabetes Federation (IDF) estimates that approximately 589 million adults worldwide currently live with diabetes, a number projected to rise to 643 million by 2030.

The relationship between obesity and diabetes has created a self-reinforcing disease cycle. Excess adiposity drives insulin resistance, which in turn increases the risk of cardiovascular complications including heart attack, stroke, and kidney disease. These complications represent the largest cost drivers for healthcare systems; cardiovascular disease (CVD) alone accounts for roughly one-third of deaths worldwide, causing an estimated 19.2 million deaths in 2023, according to the World Health Organization.

The ability of GLP-1 receptor agonists to address both metabolic and cardiovascular risk has transformed clinical perception. Large cardiovascular outcomes trials (CVOTs) have demonstrated that several GLP-1 therapies reduce major adverse cardiovascular events (MACE) in patients with obesity or diabetes, positioning them as potential long-term disease-modifying treatments rather than simple weight-loss drugs.

The MASH Opportunity: A New Frontier in Liver Disease

One of the fastest-growing areas within the cardiometabolic field is Metabolic Dysfunction-Associated Steatohepatitis (MASH), a progressive liver disease linked to obesity and insulin resistance.

• Disease Burden: The broader condition—metabolic dysfunction-associated steatotic liver disease (MASLD)—affects an estimated 38% of the global adult population. The more severe inflammatory form, MASH, affects approximately 5–6% of adults worldwide.
• Clinical Strategy: Untreated MASH can progress to cirrhosis, liver failure, or hepatocellular carcinoma. As viral hepatitis becomes increasingly controlled through vaccination and antiviral treatments, metabolic liver disease is emerging as the leading cause of liver transplantation in many developed countries.
• Economic Impact: Pharmaceutical companies are increasingly targeting this market. GLP-1 therapies such as semaglutide and tirzepatide are currently being evaluated in clinical trials for MASH resolution and fibrosis improvement. Analysts estimate that effective therapies for metabolic liver disease could create a global market exceeding $30 billion annually, reflecting the absence of widely approved treatments. For healthcare systems, the incentives are clear: liver transplantation can cost more than $500,000 per patient, making pharmacological intervention far more cost-effective.

Regional Variations in the Obesity Epidemic

• United States: The U.S. remains the primary market for obesity therapeutics. Data from the U.S. Centers for Disease Control and Prevention (CDC) and Gallup shows the adult obesity rate at 37.0% in 2025, a slight decrease from its 39.9% peak in 2022. Usage of GLP-1 injectables for weight loss has more than doubled in the past year, reaching 12.4% of U.S. adults.
  The financial burden is increasingly falling on employers, who provide health coverage for a large portion of the U.S. population. Rising demand for GLP-1 therapies has become a major cost driver in employer-sponsored insurance plans, prompting companies to explore stricter eligibility criteria and prior authorization requirements.
• Asia: Asia is the fastest-growing region for cardiometabolic disease. China is estimated to have the largest population of adults with overweight and obesity by 2050, reaching 627 million. Notably, Asian populations develop metabolic complications at lower BMI thresholds compared with Western populations, accelerating the need for early intervention. Rapid urbanization, dietary shifts, and reduced physical activity have accelerated obesity rates across several major economies.
  India is experiencing a similar trend. Although national obesity rates remain lower than those in Western countries, the country now has one of the largest populations of people with diabetes globally, creating substantial demand for cardiometabolic treatments.
• Middle East and Oceania: Some of the highest obesity rates globally are found in Gulf countries and parts of Oceania, where prevalence among adults can exceed 40–50%. These regions face particularly acute healthcare challenges as metabolic disease intersects with rapidly aging populations.

Healthcare Systems Under Pressure

The scale of the cardiometabolic epidemic is forcing healthcare systems to reconsider how obesity is treated. Historically, weight loss was viewed primarily as a lifestyle issue managed through diet and exercise interventions.

However, mounting evidence linking obesity to cardiovascular disease, kidney failure, and liver disease has led policymakers to reclassify obesity as a chronic, relapsing metabolic condition requiring long-term treatment. In September 2025, the WHO added GLP-1 therapies to its Essential Medicines List for managing type 2 diabetes in high-risk groups, including those with obesity or CVD.

This shift is particularly visible in Europe and North America, where health authorities are increasingly evaluating therapies based on long-term clinical outcomes rather than short-term cost considerations.

Professional societies such as the European Association for the Study of Obesity (EASO) have emphasized the importance of early pharmacological intervention in high-risk patients. The goal is to prevent downstream complications—including heart failure, dialysis, and liver transplantation—that place far greater strain on healthcare budgets.

A Shift Toward Organ-Based Disease Staging

Clinical practice is evolving beyond BMI. The Lancet Diabetes & Endocrinology Commission on Clinical Obesity recently proposed a diagnostic model based on organ dysfunction and tissue damage rather than weight alone. This framework identifies “clinical obesity” as a chronic disease associated with ongoing organ dysfunction, ensuring treatment targets patients with the highest clinical need. Specifically, treatment decisions would focus on patients with measurable metabolic damage—such as cardiovascular disease, fatty liver disease, or kidney impairment—rather than simply elevated BMI.

For pharmaceutical companies, this approach could expand the role of metabolic drugs by positioning them as treatments for systemic cardiometabolic disease rather than cosmetic weight reduction.

The Next Phase of the Cardiometabolic Economy

The convergence of obesity, diabetes, cardiovascular disease, and metabolic liver disease is reshaping both global healthcare systems and the pharmaceutical industry.

1. Value-Based Outcomes: Insurers are shifting from measuring “pounds lost” to long-term reductions in total healthcare costs, such as avoided dialysis or heart failure admissions.
2. Affordability & Generics: The WHO is urging the production of affordable generics for GLP-1 drugs as patents begin to expire, ensuring access in developing countries.
3. Combination Therapies: The next generation of drugs will target multiple metabolic pathways simultaneously—improving glucose regulation, liver health, and muscle preservation all in one.
4. Economic Inference: The “winner” in the 2027 market will be the company that proves Total Cost of Care (TCOC) reduction. If GLP-1s can show a 20% reduction in long-term kidney failure and heart failure admissions—as hinted by the 2026 AHA Heart Disease Statistics Update—the $260 billion market valuation will likely be viewed by institutional analysts as a conservative baseline.

With more than one billion people affected by obesity and hundreds of millions living with diabetes, cardiometabolic disease is poised to remain one of the largest therapeutic markets in modern medicine.

For pharmaceutical companies developing GLP-1 and next-generation incretin therapies, the challenge will be scaling manufacturing and ensuring affordability as demand expands worldwide. For healthcare systems, the challenge will be balancing the upfront cost of these therapies against their potential to prevent some of the most expensive complications in modern medicine.

Author

Bernice Lottering